Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Eli Lilly

One Of The Biggest Names In Medicine Just Entered The Obesity Melee. Here's Why Novo, Lilly Still Have An Edge.

Pharma giant Merck unveiled new data for a potential competitor to weight loss drugs from Novo Nordisk and Eli Lilly.

Investors Business Daily

Biogen Hits Buy Zone On A Fresh Win For Its Alzheimer's Treatment; Eli Lilly, Eisai Shares Jump

Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.

Investors Business Daily

Eli Lilly Could Launch Its Rival To Novo Nordisk's Weight-Loss Drug A Year Earlier Than Expected

An analyst expects Lilly to launch a competitor in weight-loss drugs a year earlier than expected, giving Eli Lilly stock a chance to shine.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Commentary: By avoiding funding Alzheimer’s research, the government is cutting seniors’ life spans

Millions of patients and their caregivers breathed a collective sigh of relief when drugmaker Eli Lilly recently announced its new experimental Alzheimer’s medication appears to slow cognitive decline by 35%. The Food and Drug Administration could approve the new treatment, donanemab, as soon as this year.

Chicago Tribune

New weekly obesity injection could help people rapidly shed body weight

The National Institute for Health and Care Excellence (Nice) is judging whether or not the jab would be a good use of NHS funds.

Daily Record

New once-a week injection helps people lose large amount of weight

The National Institute for Health and Care Excellence (Nice) is seeing whether the drug would be a good use of NHS funds

Wales Online

New obesity jab that sparked diabetes row in US could get NHS green light

Tirzepatide is currently approved by regulators for type 2 diabetes – but may soon also be approved for obesity

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly Stock Doesn't Have To Shoot Higher For Profits

If Eli Lilly stays around 440, this calendar spread profits on its neutral outlook.

Investors Business Daily

Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says.

Lilly's Alzheimer's treatment could reach blockbuster status by 2025, an analyst said Monday. Eli Lilly stock is trading near a record high.

Investors Business Daily

New Alzheimer’s drug: what you need to know about donanemab’s promising trial results

American pharmaceutical company Eli Lilly announced last week that it had seen encouraging clinical trial results of its new Alzheimer’s medication. According to the company, their experimental drug, donanemab, was shown in a late-stage trial to slow cognitive decline by 35%. While these results do sound promising, the full data…

The Conversation

New Alzheimer’s drug slows cognitive decline by a third

A new Alzheimer's drug, 'donanemab', was found to clear amyloid plaques from the brains, and slow cognitive decline by about a third.

The New Daily

Pharma firm claims drug trial slows Alzheimer’s progression by 35 per cent

A new drug given to Alzheimer's patients slowed the disease's progress by 35 per cent, the latest trial has revealed.

The New Daily

Dow Jones Falls On Peak-Rate Uncertainty; QCOM Falls While ETSY, RUN Rise After Earnings

The Dow Jones rose ahead of a Fed rate hike. Fed Chief Powell's comments suggested a rate pause. Eli Lilly surged after reporting a breakthrough Alzheimer's treatment.

Investors Business Daily

'Remarkable' Alzheimer's drug reduces cognitive decline, study shows

Washington (AFP) - US pharmaceutical giant Eli Lilly on Wednesday announced its experimental Alzheimer's drug significantly slowed cognitive and functional decline, results hailed as "remarkable" by experts despite some patients experiencing serious side effects.

AFP

Get all your
news in one place.

100’s of premium titles.
One news app.

Evening Standard

World ‘on cusp of first generation of treatments for Alzheimer’s’

Almost half of those on donanemab had no clinical progression of disease at one year compared with 29% on a placebo, a study showed.

The National (Scotland)

World ‘on the cusp of first generation of treatments for Alzheimer’s’

THE world is “on the cusp of a first generation of treatments for Alzheimer’s disease”, experts have said, as a new drug was found to slow…

The Independent UK

World ‘on cusp of first generation of treatments for Alzheimer’s’ as new drug ‘slows symptoms’

New drug donanemab appears to slow decline associated with Alzheimer’s

AFP

'Remarkable' Alzheimer drug reduces cognitive decline, results show

Washington (AFP) - US drugmaker Eli Lilly on Wednesday announced its experimental Alzheimer's drug significantly slowed cognitive and functional decline, results hailed as "remarkable" by experts.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Eli Lilly Hits A Record-Smashing $409 Billion Market Cap Following Its Alzheimer's Win

Eli Lilly stock popped Wednesday after the company said its experimental Alzheimer's treatment significantly slowed cognitive decline.

The Independent UK

World ‘on cusp of first generation of treatments for Alzheimer’s’ as new drug found

Almost half of those on donanemab had no clinical progression of disease at one year compared to 29% on placebo, a study showed.

Investors Business Daily

Dow Jones Futures: Fed Hike Due, PacWest, AMD In Focus. Eli Lilly Drug Slows Alzheimer's.

Another rate hike is expected today, but Fed guidance will be key. PacWest rebounded while AMD tumbled. Eli Lilly jumped on its Alzheimer's drug.

The Street

Eli Lilly Surges On Promising Data From Late-Stage Alzheimer's Drug Trial

"This is the first Phase 3 trial of any investigational medicine for Alzheimer's disease to deliver 35% slowing of clinical and functional decline," Eli Lilly said.

Investors Business Daily

Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?

Industry analysts warn that a groundbreaking change in how Medicare buys drugs threatens industry growth, profits — and maybe patient care.

Daily Record

New weight loss drug helping people lose 2.5 stone is 'coming to the UK'

A weekly injection of tirzepatide has seen people with obesity and diabetes lose over 15 percent of their bodyweight.

The Independent UK

Weight loss jab that can help patients shed two-and-a-half stone set for UK approval

Tirzepatide could be given to patients with diabetes or heat disease

1 … 16 17 18 19

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

128 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.